"Hemophilia B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
- Hemophilia B
- Bs, Hemophilia
- Hemophilia Bs
- Deficiency, Factor IX
- Deficiencies, Factor IX
- Factor IX Deficiencies
- Factor IX Deficiency
- Hemophilia B Leyden
- Hemophilia B(M)
- Hemophilia Bs (M)
- Plasma Thromboplastin Component Deficiency
- F9 Deficiency
- Deficiencies, F9
- Deficiency, F9
- F9 Deficiencies
- Christmas Disease
- Disease, Christmas
- Haemophilia B
- Haemophilia Bs
Below are MeSH descriptors whose meaning is more general than "Hemophilia B".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia B".
This graph shows the total number of publications written about "Hemophilia B" by people in this website by year, and whether "Hemophilia B" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Hemophilia B" by people in Profiles.
Plautz WE, Sekhar Pilli VS, Cooley BC, Chattopadhyay R, Westmark PR, Getz T, Paul D, Bergmeier W, Sheehan JP, Majumder R. Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis. Arterioscler Thromb Vasc Biol. 2018 04; 38(4):816-828.
Sherman A, Schlachterman A, Cooper M, Merricks EP, Raymer RA, Bellinger DA, Herzog RW, Nichols TC. Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods Mol Biol. 2014; 1114:413-26.
Aljamali MN, Margaritis P, Schlachterman A, Tai SJ, Roy E, Bunte R, Camire RM, High KA. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest. 2008 May; 118(5):1825-34.
Cao O, Armstrong E, Schlachterman A, Wang L, Okita DK, Conti-Fine B, High KA, Herzog RW. Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. Blood. 2006 Jul 15; 108(2):480-6.
Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 2005 Mar 15; 105(6):2316-23.
Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004 Apr; 113(7):1025-31.